ArticleJournal for immunotherapy of cancer2018

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.

Fatima Karzai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.